Advancing a Potent Inhibitor of SARS-CoV-2 3CL Protease into Clinical Trials

Tyrrell, D. Lorne J | $904,236

Alberta University of Alberta 2020 CIHR Operating Grant

The coronavirus, SARS-CoV-2, has caused COVID-19, a disease that is currently pandemic. The drug GC376 targets an enzyme in the virus that stops its replication. This drug has been used successfully to treat a fatal disease in cats known as Feline Infectious Peritonitis (FIP). FIP is caused by a coronavirus similar to the virus causing COVID-19. This study will move GC376 into phase I human trials on the path to bringing this compound to the benefit of patients with COVID-19.

With funding from the Government of Canada

Please complete this short survey to help us understand our impact. Thank you!

Give Feedback